Seroprevalence of Anti-HAV IgG in Chronic Hepatitis-B Patients

Authors

  • Zubaida Nahar Khanam Assistant Professor of Microbiology, Mainamoti Medical College, Cumilla
  • Solaiman Hossain Medical Officer, Cumilla Medical College, Cumilla
  • Md Sazzad Hossain Associate Professor of Medicine, Dhaka Medical College, Dhaka
  • Md Ali Professor of Medicine, Dhaka Medical College, Dhaka
  • Md Belalul Islam Professor of Medicine, Department of Medicine, Dhaka Medical College

DOI:

https://doi.org/10.3329/jom.v27i1.88272

Keywords:

Anti-HAV IgG, Chronic hepatitis B, Coinfection, Seroprevalence, Socioeconomic Factors, Vaccination

Abstract

Background: Hepatitis A virus (HAV) typically causes self-limiting acute hepatitis. However, in individuals with chronic hepatitis B virus infection, HAV superinfection can lead to severe, life-threatening liver complications. Identifying hepatitis B carriers immune to HAV is therefore vital for clinical management and preventive healthcare strategies.

Objective: To determine the seroprevalence of anti-HAV IgG in chronic hepatitis B patients.

Methods: This observational cross-sectional study was conducted in the Department of Medicine, Comilla Medical College Hospital, from January to June 2021. Using purposive sampling, 84 chronic hepatitis B patients were enrolled. Data were collected via a structured questionnaire, and anti-HAV IgG status was determined using a competitive ELISA technique. Statistical analysis was performed with SPSS.

Results: Among 90 chronic hepatitis B patients (75 male,15 female),the overall anti-HAV IgG seroprevalence was 72.2% (65/90), with no significant gender disparity. Contrary to established patterns, the highest prevalence was observed in the youngest age group. Seropositivity was also higher among individuals with illiteracy and those from lower socioeconomic backgrounds.

Conclusion: As no age group is fully immune to HAV and HAV superinfection in Chronic Hepatitis B patients can lead to fulminant hepatic failure,so every patient with Chronic Hepatitis B should be screened for HAV, and immunization should be done against HAV, if not already immunized.

J MEDICINE 2026; 27(1): 11-15

Downloads

Download data is not yet available.
Abstract
10
PDF
17

Downloads

Published

2026-03-16

How to Cite

Khanam, Z. N., Hossain, S., Hossain, M. S., Ali, M., & Islam, M. B. (2026). Seroprevalence of Anti-HAV IgG in Chronic Hepatitis-B Patients. Journal of Medicine, 27(1), 11–15. https://doi.org/10.3329/jom.v27i1.88272

Issue

Vol. 27 No. 1 (2026)

Section

Original Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).